Lerdelimumab Explained

Lerdelimumab (CAT-152, intended trade name Trabio) is a human monoclonal antibody and an immunosuppressive drug targeting TGF beta 2.

It was being developed to reduce scarring after glaucoma drainage surgery.^[1] Development was stopped in late 2005 after unsuccessful trial results for that condition.^[2]

Notes and References

1. . Lerdelimumab . Drugs in R&D . 3 . 2 . 106–8 . 1 February 2002 . 12001808 . 10.2165/00126839-200203020-00006 .
2. Web site: CAT abandons Trabio after second clinical trial failure . The Pharma Letter . 28 March 2005.